ES18.03 The Lung Microbiome and Lung Cancer Progression

2021 ◽  
Vol 16 (10) ◽  
pp. S838-S839
Author(s):  
L. Segal
Keyword(s):  
Lung Cancer ◽  
Cancer Progression ◽  
Lung Microbiome

scholarly journals Human Lung Microbiome on the Way to Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
Olga V. Kovaleva ◽  
Daniil Romashin ◽  
Irina B. Zborovskaya ◽  
Mikhail M. Davydov ◽  
Murat S. Shogenov ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Helicobacter Pylori ◽  
Tumor Progression ◽  
Microbial Communities ◽  
Cancer Progression ◽  
Human Lung ◽  
Lung Microbiome ◽  
Long Time ◽  
Underlying Mechanisms ◽  
Proinflammatory Factors

Recent research on cancer-associated microbial communities led to the accumulation of data on the interplay between bacteria, immune and tumor cells, the pathways of bacterial induction of carcinogenesis, and its meaningfulness for medicine. Microbial communities that have any kind of impact on tumor progression and microorganisms associated with tumors have been defined as oncobiome. Over the last decades, a number of studies were dedicated to Helicobacter pylori and its role in the progression of stomach tumors, so this correlation can be regarded as proven. Involvement of bacteria in the induction of lung cancer has been largely ignored for a long time, though some correlations between this type of cancer and lung microbiome were established. Despite the fact that in the present the microbial impact on lung cancer progression has many confirmations, the underlying mechanisms are poorly understood. Microorganisms can contribute to tumor initiation and progression through production of bacteriotoxins and other proinflammatory factors. The purpose of this review is to organize the available data on lung cancer microbiome and its role in malignant tumor progression.

scholarly journals Lung microbiome alterations in NSCLC patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Leliang Zheng ◽  
Ruizheng Sun ◽  
Yinghong Zhu ◽  
Zheng Li ◽  
Xiaoling She ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Progression ◽  
Rare Species ◽  
Common Species ◽  
Oral Microbiota ◽  
Metagenomic Sequencing ◽  
Microbial Composition ◽  
Lung Microbiome ◽  
Egfr Expression ◽  
Nsclc Patients

AbstractLung is colonized by a diverse array of microbes and the lung microbiota is profoundly involved in the development of respiratory diseases. There is little knowledge about the role of lung microbiota dysbiosis in lung cancer. In this study, we performed metagenomic sequencing on bronchoalveolar lavage (BAL) from two different sampling methods in non-small cell lung cancer (NSCLC) patients and non-cancer controls. We found the obvious variation between bronchoscopy samples and lobectomy samples. Oral taxa can be found in both bronchoscopy and lobectomy samples and higher abundance of oral taxa can be found in bronchoscopy samples. Although the NSCLC patients had similar microbial communities with non-cancer controls, rare species such as Lactobacillus rossiae, Bacteroides pyogenes, Paenibacillus odorifer, Pseudomonas entomophila, Magnetospirillum gryphiswaldense, fungus Chaetomium globosum et al. showed obvious difference between NSCLC patients and non-cancer controls. Age-, gender-, and smoking-specific species and EGFR expression-related species in NSCLC patients were detected. There results implicated that different lung segments have differential lung microbiome composition. The oral taxa are found in the lobectomy samples suggesting that oral microbiota are the true members of lung microbiota, rather than contamination during bronchoscopy. Lung cancer does not obviously alter the global microbial composition, while rare species are altered more than common species. Certain microbes may be associated with lung cancer progression.

scholarly journals Host-Microbiome Interaction in Lung Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Qiang Dong ◽  
Eric S. Chen ◽  
Chen Zhao ◽  
Chengcheng Jin
Keyword(s):  
Lung Cancer ◽  
Cancer Progression ◽  
Current Knowledge ◽  
The Body ◽  
Exciting Field ◽  
Future Directions ◽  
Lung Cancer Patients ◽  
Commensal Microbiota ◽  
Surface Areas ◽  
Lung Microbiome

Commensal microbiota has emerged as an essential biomarker and regulator of both tumorigenesis and response to cancer therapy. However, our current knowledge about microbiota in cancer has been largely limited to intestinal microbiota. As a mucosal organ harboring one of the largest surface areas in the body, the lung is exposed to a variety of microbes through inhalation and micro-aspiration, and is colonized by a diverse bacterial community in both physiological and pathological conditions. Importantly, increasing evidence has linked the lung microbiome to cancer development. Studies in lung cancer patients and mouse models have revealed tumor-associated dysregulation of the local microbiome in the lung, which in turn impacts cancer progression by shaping the tumor microenvironment and modulating the activity of tumor-infiltrating immune cells. These findings not only provide novel mechanistic insight into the biology of lung cancer but also shed light on new therapeutic targets and strategies for lung cancer prevention and treatment. The goal of this review is to discuss the key findings, remaining questions, and future directions in this new and exciting field.

The value of sperm-associated antigen 9 in lung cancer progression

2018 ◽  
Author(s):  
Merih Tepeoglu ◽  
Ebru Sebnem Ayva ◽  
B. Handan Ozdemir
Keyword(s):  
Lung Cancer ◽  
Cancer Progression

scholarly journals αvβ3 Integrin induces partial EMT independent of TGF-β signaling

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Yoshinobu Kariya ◽  
Midori Oyama ◽  
Takato Suzuki ◽  
Yukiko Kariya
Keyword(s):  
Lung Cancer ◽  
Cancer Progression ◽  
Epithelial Mesenchymal Transition ◽  
Surface Expression ◽  
Cell Surface Expression ◽  
Αvβ3 Integrin ◽  
Poor Survival ◽  
Mesenchymal Transition ◽  
Intermediate States ◽  
Tgf Β1

AbstractEpithelial–mesenchymal transition (EMT) plays a pivotal role for tumor progression. Recent studies have revealed the existence of distinct intermediate states in EMT (partial EMT); however, the mechanisms underlying partial EMT are not fully understood. Here, we demonstrate that αvβ3 integrin induces partial EMT, which is characterized by acquiring mesenchymal phenotypes while retaining epithelial markers. We found αvβ3 integrin to be associated with poor survival in patients with lung adenocarcinoma. Moreover, αvβ3 integrin-induced partial EMT promoted migration, invasion, tumorigenesis, stemness, and metastasis of lung cancer cells in a TGF-β-independent fashion. Additionally, TGF-β1 promoted EMT progression synergistically with αvβ3 integrin, while a TGF-β signaling inhibitor showed no effect on αvβ3 integrin-induced partial EMT. Meanwhile, the microRNA-200 family abolished the αvβ3 integrin-induced partial EMT by suppressing αvβ3 integrin cell surface expression. These findings indicate that αvβ3 integrin is a key inducer of partial EMT, and highlight a new mechanism for cancer progression.

Sign in / Sign up

Export Citation Format

Share Document